Literature DB >> 24168981

Prevalence of hepatitis E virus antibodies in children in Germany.

Andi Krumbholz1, Anne Neubert, Sebastian Joel, Hermann Girschick, Hans-Iko Huppertz, Petra Kaiser, Johannes Liese, Andrea Streng, Tim Niehues, Jochen Peters, Axel Sauerbrey, Horst Schroten, Tobias Tenenbaum, Stefan Wirth, Roland Zell, Andreas Sauerbrei.   

Abstract

BACKGROUND: Since asymptomatic hepatitis E virus (HEV) infections particularly affect children, there is a need for studies to determine the HEV seroprevalence among infants, children and adolescents.
METHODS: The prevalence of anti-HEV IgG antibodies was determined in sera taken in 2008-2010 from 1646 children aged 0-17 years living in Germany. Antibody testing was carried out using the enzyme-linked immunosorbent assay recomWell HEV IgG as well as the recomLine HEV IgG/IgM distributed by Mikrogen. Furthermore, the performance of MP Biomedicals enzyme-linked immunosorbent assay HEV and the HEV-Ab enzyme-linked immunosorbent assay from Axiom was analyzed in comparison with the recomWell/recomLine test system using a defined subset of sera.
RESULTS: In children, the overall prevalence of antibodies was 1.0%. Starting with the 5- to 6-year olds, there was a significant increase of HEV seroprevalence to 1.5% in the group of the 15- to 17-year olds. There was no statistically significant difference between seroprevalences of boys (1.2%) and girls (0.7%). Passively transmitted maternal antibodies persisted for about 3 months. The strength of agreement between the recomWell/recomLine system and the ELISAs from MP Biomedicals or Axiom varied between 0.229 and 0.542 and was calculated at 0.111 when the assays from MP Biomedicals and Axiom were compared.
CONCLUSIONS: In Germany, only a very small number of HEV infections occur in children. Many infections occur in adults with increasing age. Because of considerable variations in assay accordance, there is an urgent need for standardization of HEV serology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24168981     DOI: 10.1097/INF.0000000000000077

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

1.  Prevalence, morbidity, and therapy of hepatitis E virus infection in pediatric renal allograft recipients.

Authors:  Stephanie E Cordts; Lukas Schneble; Paul Schnitzler; Jürgen J Wenzel; Tobias Vinke; Susanne Rieger; Alexander Fichtner; Burkhard Tönshoff; Britta Höcker
Journal:  Pediatr Nephrol       Date:  2018-03-02       Impact factor: 3.714

2.  Performance of Hepatitis E Virus (HEV)-antibody tests: a comparative analysis based on samples from individuals with direct contact to domestic pigs or wild boar in Germany.

Authors:  Frauke Mara Sommerkorn; Birgit Schauer; Thomas Schreiner; Helmut Fickenscher; Andi Krumbholz
Journal:  Med Microbiol Immunol       Date:  2017-04-10       Impact factor: 3.402

3.  Seroprevalence of hepatitis E virus (HEV) in humans living in high pig density areas of Germany.

Authors:  Andi Krumbholz; Sebastian Joel; Paul Dremsek; Anne Neubert; Reimar Johne; Ralf Dürrwald; Mario Walther; Thomas H Müller; Detlef Kühnel; Jeannette Lange; Peter Wutzler; Andreas Sauerbrei; Rainer G Ulrich; Roland Zell
Journal:  Med Microbiol Immunol       Date:  2014-04-18       Impact factor: 3.402

Review 4.  Hepatitis E Virus in Industrialized Countries: The Silent Threat.

Authors:  Pilar Clemente-Casares; Carlota Ramos-Romero; Eugenio Ramirez-Gonzalez; Antonio Mas
Journal:  Biomed Res Int       Date:  2016-12-14       Impact factor: 3.411

5.  Hepatitis E virus seroprevalence in pregnant women in Jiangsu, China, and postpartum evolution during six years.

Authors:  Guangyu Gu; Hongyu Huang; Le Zhang; Yongchun Bi; Yali Hu; Yi-Hua Zhou
Journal:  BMC Infect Dis       Date:  2015-12-09       Impact factor: 3.090

6.  Detection and Characterization of Hepatitis E Virus Genotype 3 in Wastewater and Urban Surface Waters in Germany.

Authors:  Sophia Beyer; Regine Szewzyk; Regina Gnirss; Reimar Johne; Hans-Christoph Selinka
Journal:  Food Environ Virol       Date:  2020-03-14       Impact factor: 2.778

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.